Mode
Text Size
Log in / Sign up

RCD chemotherapy in Waldenström macroglobulinemia with AL amyloidosis led to rapid progression and death

RCD chemotherapy in Waldenström macroglobulinemia with AL amyloidosis led to rapid progression and…
Photo by Navy Medicine / Unsplash
Key Takeaway
Note that RCD chemotherapy in this rare case resulted in rapid progression and death from multiple organ failure.

A case report and literature review examined the clinical course of a single 75-year-old female patient diagnosed with Waldenström macroglobulinemia and AL lambda-type amyloid nephropathy. The patient received chemotherapy consisting of rituximab, cyclophosphamide, and dexamethasone (the RCD regimen), alongside symptomatic supportive therapy. This intervention occurred within a clinical practice setting rather than a controlled trial environment.

Following treatment initiation, the patient demonstrated temporary improvement in clinical symptoms and laboratory parameters. However, this initial response was not sustained. The patient subsequently experienced rapid disease progression. Follow-up data were collected approximately three months after discharge.

The primary outcome of disease progression was unfavorable, culminating in the patient's death. The cause of death was attributed to multiple organ failure involving cardiac, renal, and respiratory dysfunction. No specific adverse events or tolerability data were reported beyond this fatal outcome. The study did not report statistical significance or confidence intervals, as is typical for single-patient case reports. Limitations inherent to this study design include the small sample size of one patient and the lack of a control group, which restricts the ability to draw broad causal conclusions. The findings may offer clinical guidance for similar rare cases but require cautious interpretation due to the lack of generalizability.

Study Details

Study typeGuideline
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Waldenström macroglobulinemia (WM) is a rare CD20-positive B-cell non-Hodgkin lymphoma. It is characterized by lymphoplasmacytic infiltration in the bone marrow and abnormal monoclonal IgM secretion. WM complicated by renal amyloidosis is uncommon but associated with rapid progression of organ damage. Accurate identification of pathogenic factors and individualized treatments are essential to improve prognosis. This paper reports the case of a 75-year-old female who initially presented with facial edema and bilateral lower-extremity edema lasting 2 days. Additional symptoms included foamy urine, frequent urination, and urgency. Laboratory tests revealed significant proteinuria (24-h urinary protein, 6.11 g), hypoalbuminemia (serum albumin, 20.07 g/L), and impaired renal function (serum creatinine, 129.90 μmol/L; eGFR, 45.2 mL/min/1.73 m2). Immunofixation electrophoresis detected monoclonal IgM-λ immunoglobulin in both serum and urine. Bone marrow biopsy demonstrated clonal lymphoplasmacytic infiltration (32%), and genetic testing revealed a positive MYD88-L265P mutation (mutation frequency, 28.5%). Renal biopsy indicated diffuse deposition of λ light chains predominantly in the glomerular mesangium. Ultrastructural examination revealed amyloid fibrils, confirming the diagnosis of AL λ − type amyloid nephropathy. Chemotherapy with rituximab, cyclophosphamide, and dexamethasone (RCD regimen), combined with symptomatic supportive therapy, resulted in temporary improvement of clinical symptoms and laboratory parameters. However, the disease progressed rapidly. The patient died on Jan 28, 2024, approximately 3 months after discharge, due to multiple organ failure involving cardiac, renal, and respiratory dysfunction. Based on relevant literature and the Chinese Expert Consensus on Diagnosis and Treatment of Lymphoplasmacytic Lymphoma (LPL)/WM (2022 Edition) [Abstract 3], this paper discusses diagnostic criteria, differentiation of pathogenic components, treatment strategies, and prognostic factors. These findings may provide clinical guidance for similar rare cases.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.